Rescue video of entangled bird highlights rising toll of fishing gear on South Florida wildlife

A video posted by the Pelican Harbor Seabird Station showing the rescue of a night heron caught in fishing line has drawn more than 13,000 views in less than 24 hours-and renewed attention to the growing impact of fishing-related injuries on native wildlife in South Florida.
Rescue captured on video
The Pelican Harbor Seabird Station, located near North Bay Village, shared the footage on social media, showing the bird dangling from a tree as volunteers coordinated their rescue plan.
"We don't know how long the bird had been there. He was alive. You could see he was alive because he was trying to fly away and release himself," said Marianna Niero, the station's communications manager.
Despite their efforts, the night heron did not survive. Niero said such rescues have become almost a daily occurrence at their center off the 79th Street Causeway.
Human impact behind most injuries
So far in 2025, the station has rescued 1,047 animals. According to the organization, 90 percent of those injuries are caused by human activity-most of them fishing-related.
"I can tell you that 70 percent of our seabirds come in with some kind of injury or sickness that is due either to fishing line or a fishing hook. Or something related to fishing," Niero said.
Pelicans, seagulls, and night herons are among the most frequent patients. In one case, a bird returned with an orange band on its leg, indicating it had been treated at the facility before.
Plea for responsible fishing
Niero emphasized the importance of simple actions that could prevent these injuries.
"For people who go out and fish to just dispose properly of their fishing gear because it's super dangerous for wildlife," she said.
She also noted that South Florida's ongoing development is making matters worse, with habitat loss forcing animals into closer contact with people and urban hazards.
"With much of the habitat being dismantled for development, animals get caught in the crosshairs of everyday human life," she said.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Yahoo

35 minutes ago

• Yahoo

Acadia Pharmaceuticals (ACAD) Conducts Inducement Awards to Attract and Retain Top Talent

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is one of the 10 biotech stocks screaming a buy. On June 17, the company moved to attract and retain top talent by granting inducement awards to 41 employees. Under the 2024 Inducement Plan, the company will award the employees non-qualified stock options of 187,664 shares and 89.582 restricted stock units designed to attract and retain talent. A pharmacist in a pharmacy preparing a prescription medication for a patient suffering from Fibromyalgia. The move to offer inducement awards is part of Acadia Pharmaceuticals' push to secure top-skilled professionals essential for its neuroscience projects. It expects the awards to ensure employees are incentivized to contribute to the long-term objectives expected to lead to sustained growth and innovation. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is a biopharma company dedicated to advancing treatments for central nervous system disorders and rare diseases. Its key products include NUPLAZID, approved for Parkinson's disease psychosis, and DAYBUE. While we acknowledge the potential of ACAD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Best Software Stocks to Buy Now and 11 Must-Buy AI Stocks Analysts Are Betting On. Disclosure: None. 擷取數據時發生錯誤 登入存取你的投資組合 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤

Yahoo

35 minutes ago

• Yahoo

Ionis (IONS) Announces Leadership Transition as R&D Veteran Richard Geary Prepares to Retire

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is one of the 10 biotech stocks screaming a buy. On June 12, the company announced the upcoming retirement of Richard Geary, Ph.D., its executive vice president and chief development officer, effective January 2026. Holly Kordasiewicz, Ph.D., currently senior vice president of neurology, will take over the role. Geary has been with Ionis since 1995 and played a pivotal role in bringing six medicines to regulatory approval, including the company's first independently commercialized drug, TRYNGOLZA. A biotechnologist pouring liquid into a test tube and analyzing its components in a lab. Dr. Kordasiewicz, who joined Ionis in 2011, brings over 20 years of experience in R&D, particularly in neurology. She leads the company's neurology program, covering treatments for conditions such as Alzheimer's disease, Angelman syndrome, and Alexander disease. Her work has also contributed to key partnered programs with Biogen, including the development of QALSODY® and IONIS-MAPTRx. As Dr. Geary transitions out of his role, he will continue as a strategic consultant through 2026 to ensure continuity. Ionis leadership praised both Geary's legacy and Kordasiewicz's appointment as a pivotal step in driving the company's commitment to developing transformational therapies for patients with serious diseases. Ionis Pharmaceuticals, Inc. is a U.S.-based commercial-stage biotech company specializing in RNA-targeted therapies. Its approved products include TRYNGOLZA for FCS, WAINUA, and TEGSEDI for ATTRv-PN, SPINRAZA for spinal muscular atrophy, QALSODY for ALS, and WAYLIVRA for rare lipid disorders. The company has a robust pipeline, including late-stage programs like Olezarsen (for hypertriglyceridemia), Donidalorsen (for hereditary angioedema), and Zilganerse (for Alexander disease), along with several mid-stage treatments for neurological and metabolic conditions. Ionis also collaborates with leading pharma firms, including Biogen, GSK, AstraZeneca, Novartis, Roche, and Metagenomi, expanding its reach in developing transformative RNA therapies. While we acknowledge the potential of IONS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Best Software Stocks to Buy Now and 11 Must-Buy AI Stocks Analysts Are Betting On. Disclosure: None.

Fox News

38 minutes ago

• Fox News

How Trump's decision 'charts a new path' for the Middle East

All times eastern FOX News Saturday Night with Jimmy Failla FOX News Radio Live Channel Coverage